Excitingly, in our present investigation, using the newly developed nitro Akt (Y350-NO2) antibody, we discovered that nitration of Akt at Tyr-350 residue was an early molecular modification possibly responsible for the pathogenesis and progression of PAH. Here, AKT1 is linked to pulmonary arterial hypertension.